• Erythromycin and other macrolide antibiotics inhibit the metabolism of a number of drugs (eg oral anticoagulants, carbamazepine and theophylline) resulting in potentiation of effect.
  • In penicillin-allergic patients who fail to respond to, or are unable to tolerate erythromycin, clarithromycin may be an appropriate alternative.
  • Use clarithromycin in Helicobacter pylori eradication regimes.

CLARITHROMYCIN - (First line)

Important: Therapy notes

MHRA advice: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions (February 2022) (www.gov.uk).

  • First-line choice in Helicobacter pylori eradication.  See eradication therapies.

Important: Formulation and dosage details

Formulation:

Tablets 250mg, 500mg

Important: Formulation and dosage details

Formulation:

Oral suspension 125mg/5mL

Important: Formulation and dosage details

Formulation:

Infusion 500mg

AZITHROMYCIN

Important: Therapy notes

MHRA advice: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions (February 2022) (www.gov.uk).

Important: Formulation and dosage details

Formulation:

Tablets 250mg

Important: Formulation and dosage details

Formulation:

Tablets 500mgOTC

Important: Formulation and dosage details

Formulation:

Oral suspension 200mg/5mL

ERYTHROMYCIN

Important: Therapy notes

MHRA advice: Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions (February 2022) (www.gov.uk).
MHRA advice: 
Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban (December 2020) (www.gov.uk).
MHRA advice: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis (December 2020) (www.gov.uk).

Important: Formulation and dosage details

Formulation:

Enteric coated tablets 250mg

Important: Formulation and dosage details

Formulation:

Oral suspension 125mg/5mL, 250mg/5mL

Important: Formulation and dosage details

Formulation:

Infusion 1 gram

Editorial Information

Document Id: F259